It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The validity of dementia diagnostic criteria depends on their ability to distinguish dementia symptoms from pre-existing cognitive impairments. The study aimed to assess inter-rater reliability and concurrent validity of DSM-5 criteria for neurocognitive disorder in Down syndrome. The utility of mild neurocognitive disorder as a distinct diagnostic category, and the association between clinical symptoms and neurodegenerative changes represented by the plasma biomarker neurofilament light were also examined. 165 adults with Down syndrome were included. Two clinicians independently applied clinical judgement, DSM-IV, ICD-10 and DSM-5 criteria for dementia (or neurocognitive disorder) to each case. Inter-rater reliability and concurrent validity were analysed using the kappa statistic. Plasma neurofilament light concentrations were measured for 55 participants as a marker of neurodegeneration and between group comparisons calculated. All diagnostic criteria showed good inter-rater reliability apart from mild neurocognitive disorder which was moderate (k = 0.494). DSM- 5 criteria had substantial concurrence with clinical judgement (k = 0.855). When compared to the no neurocognitive disorder group, average neurofilament light concentrations were higher in both the mild and major neurocognitive disorder groups. DSM-5 neurocognitive disorder criteria can be used reliably in a Down syndrome population and has higher concurrence with clinical judgement than the older DSM-IV and ICD-10 criteria. Whilst the inter-rater reliability of the mild neurocognitive disorder criteria was modest, it does appear to identify people in an early stage of dementia with underlying neurodegenerative changes, represented by higher average NfL levels.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 King’s College London, Institute of Psychiatry, Psychology, and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839); King’s College London, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and Neuroscience, London, England (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
2 King’s College London, Centre for Developmental Neurobiology and MRC Centre for Neurodevelopmental Disorders, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
3 King’s College London, Institute of Psychiatry, Psychology, and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia, London, UK (GRID:grid.454378.9); Sahlgrenska Academy at the University of Gothenburg, Department of Psychiatry and Neurochemistry, Mölndal, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); University of Gothenburg, Wallenberg Centre for Molecular and Translational Medicine, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
4 King’s College London, Institute of Psychiatry, Psychology, and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia, London, UK (GRID:grid.454378.9)
5 University College London, Division of Psychiatry, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
6 East London NHS Foundation Trust, London, UK (GRID:grid.450709.f) (ISNI:0000 0004 0426 7183)
7 Camden and Islington Mental Health Foundation Trust, London, UK (GRID:grid.474126.2) (ISNI:0000 0004 0381 1108)
8 Parnassia Psychiatric Institute, The Hague, The Netherlands (GRID:grid.474126.2)
9 University College London, Division of Psychiatry, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201); Barnet Enfield and Haringey Mental Health NHS Trust, London, UK (GRID:grid.439448.6) (ISNI:0000 0004 0399 6472)
10 South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839)
11 North East London NHS Foundation Trust, London, UK (GRID:grid.451079.e) (ISNI:0000 0004 0428 0265)
12 NHS Foundation Trust, Lancashire and South Cumbria, Lancashire, UK (GRID:grid.451052.7) (ISNI:0000 0004 0581 2008)
13 Southern Health NHS Foundation Trust, London, UK (GRID:grid.467048.9) (ISNI:0000 0004 0465 4159)
14 King’s College London, Institute of Psychiatry, Psychology, and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839)




